| scholarly article | Q13442814 |
| P2093 | author name string | Anand Ramamurthi | |
| Dhruv R Seshadri | |||
| P2860 | cites work | Carboxyl- and amino-functionalized polystyrene nanoparticles differentially affect the polarization profile of M1 and M2 macrophage subsets. | Q53796245 |
| Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002 | Q57116039 | ||
| Biodegradable polymeric nanocarriers for pulmonary drug delivery | Q57381746 | ||
| p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment | Q80798294 | ||
| Mannose-targeted systems for the delivery of therapeutics | Q81406406 | ||
| Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy | Q84893197 | ||
| Nanoparticle immunotherapy: Combo combat | Q87354087 | ||
| The COPD pipeline | Q87435719 | ||
| Size influences the cytotoxicity of poly (lactic-co-glycolic acid) (PLGA) and titanium dioxide (TiO(2)) nanoparticles. | Q42626462 | ||
| Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images. | Q42659721 | ||
| Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature | Q43201316 | ||
| Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization | Q43672804 | ||
| Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. | Q46189905 | ||
| EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin | Q46581631 | ||
| Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer | Q46627272 | ||
| Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent | Q47230465 | ||
| Multifunctional, JNK-inhibiting nanotherapeutics for augmented elastic matrix regenerative repair in aortic aneurysms | Q47712218 | ||
| Hospitalizations due to exacerbations of COPD: A big data perspective | Q49343017 | ||
| Magnetically-responsive, multifunctional drug delivery nanoparticles for elastic matrix regenerative repair. | Q51046054 | ||
| Medical nanoparticles for next generation drug delivery to the lungs. | Q51726084 | ||
| Mitochondria-Targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo. | Q51820385 | ||
| Glycocalyx-Mimicking Nanoparticles for Stimulation and Polarization of Macrophages via Specific Interactions. | Q53229502 | ||
| Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. | Q53563312 | ||
| Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles | Q24536032 | ||
| Exploring the full spectrum of macrophage activation | Q24653754 | ||
| Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy | Q26777144 | ||
| Modulation of the tumor microenvironment for cancer treatment: a biomaterials approach | Q26996790 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| The new toxicology of sophisticated materials: nanotoxicology and beyond | Q28390743 | ||
| Magnetic core-shell nanoparticles for drug delivery by nebulization | Q28393991 | ||
| Endothelial cell heterogeneity | Q28740296 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| The M1 and M2 paradigm of macrophage activation: time for reassessment | Q29615845 | ||
| Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord | Q29619388 | ||
| Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection. | Q30370370 | ||
| Shedding light on nanomedicine. | Q30447871 | ||
| In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. | Q39126600 | ||
| Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. | Q39176028 | ||
| Nanoparticles for tumor immunotherapy | Q39190035 | ||
| Progress in tumor-associated macrophage (TAM)-targeted therapeutics | Q39267549 | ||
| Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy. | Q39312034 | ||
| Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer | Q39314913 | ||
| Lomustine loaded chitosan nanoparticles: characterization and in-vitro cytotoxicity on human lung cancer cell line L132. | Q39581887 | ||
| Transcriptional and posttranscriptional inhibition of lysyl oxidase expression by cigarette smoke condensate in cultured rat fetal lung fibroblasts | Q39685428 | ||
| Multifunctional nanoparticles for doxycycline delivery towards localized elastic matrix stabilization and regenerative repair. | Q39754185 | ||
| Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. | Q40091549 | ||
| Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. | Q40119549 | ||
| Cytokine production by alveolar macrophages is down regulated by the alpha-methylhydroxylation pathway of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). | Q40592288 | ||
| Role of Proteases in Chronic Obstructive Pulmonary Disease. | Q41333629 | ||
| Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation | Q41471366 | ||
| Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles. | Q41720775 | ||
| A549 lung cell line activity of biosynthesized silver nanoparticles using Albizia adianthifolia leaf | Q30586315 | ||
| Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. | Q33530006 | ||
| Cancer associated fibroblasts in cancer pathogenesis | Q33664004 | ||
| TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population | Q33743051 | ||
| Targeting and in vivo imaging of non-small-cell lung cancer using nebulized multimodal contrast agents. | Q33835121 | ||
| Strategies for advancing cancer nanomedicine | Q33995719 | ||
| State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines | Q34045119 | ||
| Development of inhalational agents for oncologic use. | Q34184159 | ||
| Mechanistic links between COPD and lung cancer | Q34331434 | ||
| Programmed death ligand-1 expression in non-small cell lung cancer | Q34384255 | ||
| Distinct fibroblast lineages determine dermal architecture in skin development and repair. | Q34391786 | ||
| Influence of pH on extracellular matrix preservation during lung decellularization. | Q34563085 | ||
| Delivering nanomedicine to solid tumors | Q34726981 | ||
| Is a regenerative approach viable for the treatment of COPD? | Q34903164 | ||
| Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung | Q35237421 | ||
| Tumour macrophages as potential targets of bisphosphonates. | Q35547309 | ||
| An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion | Q35703670 | ||
| Cancer stem cells: impact, heterogeneity, and uncertainty | Q35857599 | ||
| Nanoparticle and targeted systems for cancer therapy | Q35879221 | ||
| Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma | Q36045203 | ||
| Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases | Q36068489 | ||
| Mesenchymal stem cells engineered for cancer therapy | Q36092724 | ||
| Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology | Q36321710 | ||
| Elastin synthesis and fiber assembly | Q36398637 | ||
| The stumbling block in lung repair of emphysema: elastic fiber assembly | Q36518608 | ||
| Advances in biomimetic regeneration of elastic matrix structures | Q36552037 | ||
| Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach | Q36612202 | ||
| Inhaling medicines: delivering drugs to the body through the lungs | Q36694800 | ||
| Tumor microenvironment: the role of the tumor stroma in cancer | Q36709404 | ||
| A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer | Q36776738 | ||
| Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. | Q36781516 | ||
| Magnetically Responsive Bone Marrow Mesenchymal Stem Cell-Derived Smooth Muscle Cells Maintain Their Benefits to Augmenting Elastic Matrix Neoassembly | Q36786066 | ||
| Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo | Q36887407 | ||
| Use of Respimat Soft Mist inhaler in COPD patients | Q37018826 | ||
| Defect of alveolar regeneration in pulmonary emphysema: role of lung fibroblasts | Q37082579 | ||
| Tissue regeneration as next-generation therapy for COPD--potential applications | Q37115944 | ||
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Q37153923 | ||
| Principles of nanoparticle design for overcoming biological barriers to drug delivery | Q37162182 | ||
| Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases | Q37167333 | ||
| First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel | Q37419857 | ||
| Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues | Q37543916 | ||
| Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy | Q37590998 | ||
| Lung parenchymal mechanics | Q37593501 | ||
| Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles | Q37624646 | ||
| The Current State of Nanoparticle-Induced Macrophage Polarization and Reprogramming Research | Q37690819 | ||
| The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect | Q37742217 | ||
| To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery | Q37783377 | ||
| Non-small-cell lung cancer. | Q37874768 | ||
| Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases | Q37883025 | ||
| Nanoparticles: a review of particle toxicology following inhalation exposure | Q37977147 | ||
| Doxil®--the first FDA-approved nano-drug: lessons learned | Q38000876 | ||
| Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system | Q38038897 | ||
| Cancer nanomedicine: from drug delivery to imaging | Q38172476 | ||
| Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors | Q38200821 | ||
| Non-small-cell lung cancers: a heterogeneous set of diseases | Q38233321 | ||
| Extracellular matrix as a driver for lung regeneration | Q38262619 | ||
| Nanoparticle-based immunotherapy for cancer | Q38282133 | ||
| Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery | Q38333122 | ||
| Inhalation drug delivery devices: technology update | Q38364686 | ||
| Nanomedicines Targeting the Tumor Microenvironment | Q38556806 | ||
| Nanotechnology approaches for inhalation treatment of lung diseases | Q38571420 | ||
| Alveolar Macrophage Polarisation in Lung Cancer | Q38575761 | ||
| Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. | Q38684280 | ||
| Methods in elastic tissue biology: elastin isolation and purification | Q38738075 | ||
| Cathepsin K-targeted sub-micron particles for regenerative repair of vascular elastic matrix. | Q38770544 | ||
| Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer | Q38809683 | ||
| Nanoparticle-based targeted gene therapy for lung cancer | Q38854207 | ||
| Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations | Q38885341 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 759 | |
| P577 | publication date | 2018-07-16 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease | |
| P478 | volume | 9 |
Search more.